Syndax Pharmaceuticals
在场
高管
查看带有其 17 名主要高管的组织结构图
Syndax Pharmaceuticals 搜索最多的简介
- Michael Metzger, Director and Chief Executive Officer
- Jennifer Jarrett, Director
- Pierre Legault, Director
高管在Syndax Pharmaceuticals变化
- Steve Sabus, Chief Commercial Officer, 已经离开公司 (新闻发布的2024三月24号).
- Steven Closter已作为Chief Commercial Officer加入公司 (新闻发布的2024三月24号).
创建提醒
跟踪 Syndax Pharmaceuticals 的高管变动
药店
Syndax Pharmaceuticals 拥有 1,861 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Johnson & Johnson (美国(美洲))。
Popular M&A news in 药店
- MedMen has filed for bankruptcy protection (公布2024四月28号).
- AstraZeneca has announced the acquisition of Fusion Pharma (公布2024三月23号).
- AstraZeneca has announced the acquisition of Amolyt Pharma (公布2024三月19号).
药店 行业的其他推荐联系人
消息
Syndax Pharmaceuticals 的最新新闻稿
- Syndax Announces Participation at Stifel Healthcare Conference | Syndax Pharmaceuticals, Inc.
- Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis | Syndax Pharmaceuticals, Inc.
- Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023 | Syndax Pharmaceuticals, Inc.
- Syndax Announces Participation at the Citi 18th Annual BioPharma Conference | Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update | Syndax Pharmaceuticals, Inc.
- Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease | Syndax Pharmaceuticals, Inc.
- Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023 | Syndax Pharmaceuticals, Inc.
- Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022 | Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) | Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer | Syndax Pharmaceuticals, Inc.
- View more press releases Close
通过电子邮件
